ISS
Epidemiology for public health
Istituto Superiore di Sanità
Epidemiology for public health - ISS

Italian immunization schedule

Hexavalent vaccine (DTaP/IPV/HepB/Hib): 1st dose

  • Protects against diphtheria, tetanus, pertussis , polio, hepatitis B and infection with Haemophilus influenzae type b

Pneumococcal conjugate vaccine (PCV): 1st dose

  • Protects against infections caused by the bacterium Streptococcus pneumoniae

Meningococcal B vaccine (MenB): 1st dose (15 days after administration of the hexavalent and pneumococcal conjugate vaccines)

  • Protects against infections caused by the bacterium Neisseria meningitidis

Rotavirus vaccine (Rotavirus): 1st dose

  • Protects against rotavirus infections

Rotavirus vaccine (Rotavirus): 2nd dose

  • Protects against rotavirus infections

Meningococcal B vaccine (MenB): 2nd dose (1 month after the 1st dose)

  • Protects against infections caused by the bacterium Neisseria meningitidis

Hexavalent vaccine (DTaP/IPV/HepB/Hib): 2nd dose

  • Protects against diphtheria, tetanus, pertussis , polio, hepatitis B and infection with Haemophilus influenzae type b

Pneumococcal conjugate vaccine (PCV): 2nd dose

  • Protects against infections caused by the bacterium Streptococcus pneumoniae

Meningococcal B vaccine (MenB): 3rd dose (1 month after the 2nd dose)

  • Protects against infections caused by the bacterium Neisseria meningitidis

Hexavalent vaccine (DTaP/IPV/HepB/Hib): 3rd dose

  • Protects against diphtheria, tetanus, pertussis , polio, hepatitis B and infection with Haemophilus influenzae type b

Pneumococcal conjugate vaccine (PCV): 3rd dose

  • Protects against infections caused by the bacterium Streptococcus pneumoniae

Quadrivalent vaccine (MMRV or MMR+V): 1st dose

  • Protects against measles, mumps, rubella and varicella

Meningococcal C conjugate vaccine (MenC)

  • Protects against infections caused by the bacterium Neisseria meningitidis

Meningococcal B vaccine (MenB): 4th dose

  • Protects against infections caused by the bacterium Neisseria meningitidis

Quadrivalent vaccine (MMRV or MMR+V): 2nd dose

  • Protects against measles, mumps, rubella and varicella

DTaP+IPV: 4th dose

  • Protects against diphtheria, tetanus, pertussis and polio

dTapIPV vaccine (formulation for adults)

  • Protects against diphtheria, tetanus, pertussis and polio

HPV vaccine

  • 2-3 doses (depending on age and vaccine) to protect against human papillomavirus infections (main cause of cervical cancer)

Meningococcal ACWY conjugate vaccine

  • Protects against infections caused by the bacterium Neisseria meningitidis

dTapIPV vaccine (formulation for adults)

  • 1 dose every 10 years to protect against diphtheria, tetanus, pertussis and polio

HPV vaccine (up to 49 years of age)

  • 2-3 doses (depending on age and vaccine) to protect against human papillomavirus infections (main cause of cervical cancer)

dTapIPV vaccine (formulation for adults)

  • 1 dose every 10 years to protect against diphtheria, tetanus, pertussis and polio

Pneumococcal conjugate and pneumococcal polysaccharide vaccines (PCV+PPSV)

  • Protects against pneumococcal diseases

Influenza vaccine (seasonal)

  • 1 dose every year to protect against seasonal influenza

Shingles vaccine

  • Protects against shingles (herpes zoster)

 

dTap: number of doses depends on the course of vaccination (primary or booster); for women, in the third trimester of pregnancy (ideally, at the 28th week)

Hepatitis B: 3 doses, before exposure (0, 1, 6 months); 4 doses, after exposure (0, 2, 6 weeks + booster at 1 year of age) or before imminent exposure (0, 1, 2, 12)

Hib: for previously unvaccinated people of all ages who are considered at risk - number of doses as per data sheet, depending on age

PCV: up to 5 years of age, then PCV/PPSV

MMR: 2 doses at least 4 weeks apart; depending on age and evidence of immunity to varicella, co-administration with monovalent varicella vaccine or administration of quadrivalent MMRV vaccine is also possible

Varicella: 2 doses at least 4 weeks apart; depending on age and evidence of immunity to measles, mumps and rubella, co-administration of monovalent varicella vaccine and trivalent MMR vaccine or administration of quadrivalent MMRV vaccine is also possible

People at increased risk of infection should be offered meningococcal ACYW and meningococcal B vaccines - number of doses as per data sheet, depending on age

HPV: all ages as per data sheet - number of doses as per data sheet, depending on age

Influenza: all ages as per data sheet - number of doses as per data sheet, depending on age

Shingles: from 50 years of age

Hepatitis A: number of doses as per data sheet

 

ministero della Salute